Emerging Technologies

We will deliver what's next, together.

Today, every company in the medical device industry is faced with similar challenges: bringing innovations to market, improving quality and administering rigorous clinical science. We believe we're well prepared to deal with the challenges and make the most of the opportunities.

We're moving into more markets with strong leadership positions. We're more diversified, with opportunities for innovation that intersect multiple technologies and therapeutic areas. Our capabilities are broader and deeper than they have ever been. And our award-winning programs are considered to be some of the best managed and most efficient as measured across multiple benchmarks.

Our LATITUDE® Patient Management System is the most broadly adopted wireless remote patient management system for cardiac resynchronization therapy defibrillators (CRT-Ds) that connects clinicians and patients to support more comprehensive cardiac care.

Our PROMUS™ everolimus-eluting coronary stent system allows Boston Scientific to offer two fully independent and differentiated drug-eluting stent platforms.

Our TAXUS® Liberté™ paclitaxel-eluting coronary stent system is designed to offer improved deliverability and conformability in challenging anatomy, and is the best-selling drug-eluting stent outside the U.S., excluding Japan.

Above all, our success is created by our people, who have helped develop some of medicine's most important and effective technologies, and who are dedicated to helping physicians improve the lives of their patients.

Together, we can set new standards for innovation, quality and clinical science. We can give clinicians new tools to improve patients' lives. We can give patients more treatment choices. And we can make high-quality healthcare less invasive, more accessible and more cost effective.

It has always been our ambition to be the leader in the medical device markets we serve. The achievements of 2006 have now positioned us to lead the entire industry.

THE RICHEST PIPELINE IN CARDIOVASCULAR MEDICINE

Boston Scientific continues to hold leadership positions across the ever-broadening spectrum of device markets and therapeutic areas we serve. With the addition of Guidant, we've reprioritized our research and development investments to focus on restoring cardiac rhythm management (CRM) product cadence and sustaining our drug-eluting stent (DES) leadership. Below is a partial list of key products from our robust cardiovascular pipeline.

DES PIPELINE

TAXUS® Liberté™ Stent System: A second-generation stent system with improved deliverability.
TAXUS® Express 2 ™ Stent System Japan: A first-generation drug-eluting stent system.
PROMUS™ Stent System: An Everolimus-eluting stent system (second drug platform).
TAXUS® Element™ Stent System: A third-generation stent system with improved performance.
PROMUS™ Element™ Stent System: The Element stent system with everolimus drug.
TAXUS® Petal™ Stent System: A stent system for branching vessels.
Odyssey: The fourth-generation Element stent system with bioabsorbable polymers. It is the first bioabsorbable coated stent system that promotes healing.

CRM PIPELINE

Heart failure management: ACUITY™ Steerable Leads, ACUITY™ Spiral Leads, ACUITY™ Lead Delivery System, and COGNIS™ Defibrillator.
Sudden cardiac death prevention: VITALITY NXT™ Defibrillator, and the TELIGEN™ Defibrillator.
Remote patient management: The LATITUDE® Patient Management System expansion, and electronic medical record integration.
Next-generation compatible lead connectors: The IS-4 Family.